Researchers responding to critique in The Lancet Healthy Longevity argue that deprescribing trials must be built on an explicit clinical rationale before investigators select trial design, outcome measures, or analytic methods such as the win ratio. Without that foundation, studies of medication withdrawal in older adults risk producing results that cannot guide practice. The exchange addresses a methodological gap in one of the most consequential interventions in geriatric medicine.
Key Points
- Clinical rationale should precede trial design in deprescribing research
- Outcome selection and win ratio analysis follow, not lead
- Poorly framed medication-withdrawal trials yield non-actionable evidence for clinicians
Longevity Analysis
Removing medications that no longer serve a patient is among the highest-yield interventions in later life, yet the evidence base remains thin precisely because trials often begin with design questions rather than with a defensible reason to stop a given drug. Polypharmacy burdens hepatic and renal clearance, blunts cognition and balance, and generates symptoms frequently mistaken for ageing itself — a misreading that prompts further prescribing. Rigorous rationale-first methodology determines whether clinicians can act on subtraction with the same confidence they bring to addition.
Original published by The Lancet Healthy Longevity, by Catherine S Hwang, Kenneth S Boockvar, Michael A Steinman.